Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. (NASDAQ: NTRA) is a diagnostic and research company in the medical laboratories industry, focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. The Natera news feed on Stock Titan highlights company announcements, clinical data readouts, collaborations, and financial updates that reflect how its testing platforms are used in practice and research.
Recent news has featured advances in molecular residual disease (MRD) testing with Signatera, including new multi-modal AI models that integrate longitudinal circulating tumor DNA, clinical data, digital pathology, and tumor sequencing to refine recurrence risk assessment and outcomes prediction. Natera also reports on large clinical studies and trial analyses in colorectal cancer and breast cancer, where Signatera is used to evaluate MRD, predict treatment response, and support risk stratification.
In women’s health, news items include the launch and validation of Fetal Focus, a single-gene non-invasive prenatal test that uses cell-free DNA from maternal blood to assess inherited conditions when partner testing is not available, as well as updates related to the broader prenatal and carrier screening portfolio. Organ health news may cover the use of Natera’s Prospera test in transplant rejection assessment and related research.
Investors and clinicians can also follow Natera’s announcements about AI collaborations, such as its work with NVIDIA to scale multimodal AI foundation models, and corporate updates including preliminary financial results and participation in healthcare conferences. For those tracking NTRA, this news page provides a centralized view of developments across oncology, women’s health, organ health, and AI-enabled diagnostics.
Natera (NASDAQ: NTRA) will present 11 abstracts at ASCO GU (Feb 26-28, 2026) showing Signatera MRD's potential across genitourinary cancers.
Key findings include 73–77% ctDNA clearance in MIBC, Signatera-negativity linked to high two-year bladder-intact EFS (88.6% and 91%), and complementary utDNA+ctDNA perioperative stratification.
Natera (NASDAQ: NTRA) reported strong fourth-quarter and full-year 2025 results with significant revenue, margin, volume, and cash improvements.
Total revenue was $665.5M in Q4 2025 (+39.8% YoY) and $2,306.1M for FY2025 (+35.9%). Gross margin improved to 66.9% in Q4 and 64.7% for FY2025. Tests processed rose ~15.0% for the year, and the company achieved a positive cash inflow of $107.6M for FY2025.
Natera (NASDAQ: NTRA) reported Phase 2 SINERGY results in recurrent/metastatic head and neck squamous cell carcinoma showing a 63% objective response rate (17/27) and ctDNA-guided de-escalation in 74% of patients (20/27). Median chemotherapy exposure fell to 2 cycles versus a 6-cycle standard, with grade ≥3 toxicity at 48.1%. Data were presented as an oral plenary at the 2026 MHNCS.
Natera (NASDAQ: NTRA) will release its fourth quarter and full year 2025 results after market close on February 26, 2026. A conference call and webcast will follow at 1:30 p.m. PT / 4:30 p.m. ET.
Investors can join via dial-in (Conference ID 7684785) or the webcast link; a replay will be available at the company investor site.
Natera (NASDAQ: NTRA) launched EDEN, a large U.S. prospective study to evaluate a non-invasive prenatal screening test for early risk assessment of preeclampsia and other adverse pregnancy outcomes. The study plans to enroll up to 7,500 participants at 9–15 weeks' gestation and combines cfDNA, additional analytes, and clinical data.
EDEN builds on prior research linking cfDNA markers to pregnancy complications and aims to detect earlier-onset and more severe preeclampsia with routine prenatal data.
Natera (NASDAQ: NTRA) submitted a premarket approval (PMA) to the U.S. FDA for Signatera CDx to detect molecular residual disease (MRD) in muscle-invasive bladder cancer (MIBC) patients who may benefit from atezolizumab.
The PMA is supported by randomized, double-blind phase 3 IMvigor011 data showing Signatera-guided therapy improved disease-free and overall survival for Signatera-positive patients, while Signatera-negative patients had low recurrence risk without adjuvant immunotherapy. Results were presented at ESMO and published in The New England Journal of Medicine.
Natera (NASDAQ: NTRA) completed enrollment in ACES-EMB, the first randomized-controlled trial comparing donor-derived cell-free DNA (dd-cfDNA) surveillance with routine endomyocardial biopsy (EMB) for heart transplant rejection monitoring.
The trial enrolled >300 patients across 17 U.S. transplant centers; participants randomized at one month post-transplant will be followed for 12 months.
Natera (NASDAQ: NTRA) announced a prospective clinical trial of the Prospera dd-cfDNA test in 78 lung-transplant recipients that evaluated whether monitoring could allow omission of the routine 9-month transbronchial biopsy. Prospera testing at ~8 months classified patients as low risk (<1.0% dd-cfDNA) or high risk (≥1.0%). Physicians omitted the 9-month biopsy in ~75% of low-risk patients. Over the next 3 months and at 12 months, patients who omitted the biopsy showed similar acute rejection rates, spirometry, and donor-specific antibody outcomes, and ~95% had no treated acute rejection at one year.
Natera (NASDAQ: NTRA) published a peer-reviewed validation of its Latitude tissue-free MRD (tfMRD) assay in colorectal cancer in npj Precision Oncology, analyzing 1,230 timepoints from 195 patients in the GALAXY trial.
Key results: longitudinal sensitivity 84.4% with a median lead time of 4.6 months before radiographic recurrence; sample-level specificity 97.2% and patient-level specificity 92.1%; MRD-positivity strongly prognostic (HR 10 in MRD setting; HR 31.9 in surveillance; p<0.001). In high-risk stage II/III patients, MRD-positive status predicted substantial adjuvant chemotherapy benefit (adj.HR=0.014, P<0.0001). The study supports a MolDX submission to CMS and notes Latitude complements tumor-informed Signatera when tissue is unavailable.
Natera (NASDAQ: NTRA) announced that the EXPAND clinical trial of its Fetal Focus™ single gene NIPT (sgNIPT) will be presented as an oral plenary at the Society for Maternal Fetal Medicine (SMFM) meeting, February 8-13, 2026.
EXPAND is a prospective, blinded trial validating Fetal Focus, which uses Natera’s LinkedSNP™ technology to assess inheritance of disease-causing variants across 21 genes for serious, early-onset conditions. The oral plenary will present key results, study design, and confirmation of outcomes against genetic truth. Natera will also present VANISH data validating Panorama™ NIPT interpretation in vanishing twin pregnancies and other related posters and oral presentations on February 11–12, 2026.